Patent Law Weblog
recent posts
- Why the Alice Test is Stupid, Part IV: The Usefulness Paradox
- Teva Capitulates to Federal Trade Commission Coercion
- USPTO Issues Memoranda on Subject Matter Eligibility
- USPTO Revokes Guidance on AI-Assisted Inventorship, But Rules Remain Basically the Same
- Why the Alice Test is Stupid, Part III: Eligible Independent Claims Can Have Ineligible Dependent Claims
about
Category: Licensing
-
By Donald Zuhn — Last week, the Federal Circuit determined that Plaintiff-Appellant AsymmetRx, Inc. did not have standing to bring an action for infringement of the patents-at-suit absent the participation of the President and Fellows of Harvard College. As a result, the CAFC vacated and remanded an order by the District Court for the…
-
By Donald Zuhn — Last month, Alnylam Pharmaceuticals announced that it would contribute more than 1,500 of its RNA interference (RNAi) patents to the patent pool established by GlaxoSmithKline earlier this year. Alnylam is known for the development of therapeutics based on RNAi for the treatment of respiratory syncytial virus (RSV) infection, liver cancer,…
-
By Jason Derry — Peptimmune and Novartis Sign $500 Million Deal Peptimmune Inc. and Novartis AG recently announced a licensing deal for Peptimmune's multiple sclerosis drug candidate, PI-2301. The deal gives Novartis an exclusive license to the drug candidate. Novartis will assume all responsibilities relative to clinical development, manufacturing, and marketing of PI-2301. The…
-
By Jason Derry — Endo to Acquire Indevus On January 5, 2009, Endo Pharmaceuticals Holdings Inc. announced that it will buy Indevus Pharmaceuticals Inc. for an initial payment of about $370 million and an additional $267 million, based on certain milestones. Currently, Indevus has marketed products for the treatment of overactive bladder, prostate cancer,…
-
By Donald Zuhn — Earlier this month, Cellectis SA, based in Romainville Cedex, France, announced that it had reached an agreement with Regeneron Pharmaceuticals, Inc., of Tarrytown, NY, concerning the use of the French biotech company’s homologous recombination patent estate. Under the agreement, Regeneron would pay the French biotech company $12.45 million for…
-
By Jason Derry — Sigma-Aldrich Co. has announced a licensing deal with NeuroSurvival Technologies Ltd. by which Sigma-Aldrich will be allowed to market and manufacture a marker that can detect apoptosis in vitro and in vivo. The marker, commercially known as Apo-TRACE, is one of a number of small molecules, referred to collectively…
-
By Jason Derry — Pfizer Inc. has announced that it has an agreement in place to acquire Encysive Pharmaceuticals Inc. for about $195 million. Encysive is a biotechnology company that has a product currently marketed in the European Union, and several other foreign markets, for treating pulmonary arterial hypertension. The product, THELIN (sitaxsentan…
-
By Christopher P. Singer — On February 7, 2008, Human Genome Sciences, Inc. (HGS) and Xencor, Inc. announced that the two companies will enter a collaboration agreement relating to Xencor’s proprietary XmAb™ humanization and optimization technologies. Xencor’s technology will be applied to several new monoclonal antibody drug candidates developed against antigens discovered by…
-
Monsanto Prevails Again against Infringing Farmer By Kevin E. Noonan — In recent weeks, Monsanto has prevailed in patent infringement lawsuits involving its patented seeds from various crop species genetically engineered to be resistant to glyphosate herbicides such as Roundup® (also a Monsanto product). The U.S. Supreme Court recently refused to grant certiorari…
-
By Donald Zuhn — Last week, Swiss drug maker Novartis AG agree to supply its cancer drug Glivec® at no cost to patients in Thailand in exchange for the Thai government’s agreement not to issue a compulsory license on Novartis’ patent. Glivec® (imatinib), which is sold as Gleevac® (imatinib mesylate) in the U.S.,…
Patent Docs 